Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 24 8 2019
medline: 9 6 2020
entrez: 24 8 2019
Statut: ppublish

Résumé

The 4 component meningococcus B vaccine (4CMenB) vaccine is the first vaccine containing recombinant proteins licensed for the prevention of invasive meningococcal disease caused by meningococcal serogroup B strains. 4CMenB contains 3 main recombinant proteins, including the

Identifiants

pubmed: 31442074
doi: 10.1096/fj.201900374R
pmc: PMC6902690
doi:

Substances chimiques

4CMenB vaccine 0
Antibodies, Monoclonal 0
Antigens, Bacterial 0
Bacterial Proteins 0
Epitopes 0
Meningococcal Vaccines 0
factor H-binding protein, Neisseria meningitidis 0
Complement Factor H 80295-65-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12099-12111

Références

FASEB J. 2014 Apr;28(4):1644-53
pubmed: 24371123
Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S103-S112
pubmed: 27129415
Biologicals. 2000 Sep;28(3):193-7
pubmed: 10964447
Expert Rev Vaccines. 2015;14(9):1277-87
pubmed: 26204792
Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13
pubmed: 16203934
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Vaccine. 2003 Jun 1;21 Suppl 2:S110-3
pubmed: 12763692
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
Clin Infect Dis. 2010 Nov 15;51(10):1127-37
pubmed: 20954968
BMC Bioinformatics. 2010 Dec 10;11:595
pubmed: 21143983
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3304-9
pubmed: 23396847
Structure. 2016 Jan 5;24(1):148-157
pubmed: 26712277
J Infect Dis. 2013 Aug 15;208(4):627-36
pubmed: 23715659
Curr Opin Microbiol. 2015 Feb;23:68-72
pubmed: 25461575
PLoS One. 2012;7(3):e34272
pubmed: 22461909
J Exp Med. 2003 Mar 17;197(6):789-99
pubmed: 12642606
Expert Rev Vaccines. 2011 May;10(5):617-34
pubmed: 21604983
Infect Immun. 2011 Feb;79(2):970-81
pubmed: 21149595
mBio. 2014 Aug 26;5(5):e01625-14
pubmed: 25161192
Methods Mol Med. 2001;67:333-9
pubmed: 21337154
J Mol Biol. 1997 Nov 7;273(4):927-48
pubmed: 9367782
Infect Immun. 2011 Sep;79(9):3751-9
pubmed: 21708990
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Infect Immun. 2012 Jan;80(1):187-94
pubmed: 22064712
Lancet. 2016 Dec 3;388(10061):2775-2782
pubmed: 28100432
PLoS Pathog. 2012;8(10):e1002981
pubmed: 23133374
Vaccine. 2009 May 26;27(25-26):3417-21
pubmed: 19200847
J Mol Biol. 2009 Feb 13;386(1):97-108
pubmed: 19100746
Sci Rep. 2018 Feb 27;8(1):3700
pubmed: 29487324
Int J Epidemiol. 2001 Dec;30(6):1447-8
pubmed: 11821361
J Immunol. 2006 Jun 15;176(12):7566-75
pubmed: 16751403
J Immunol. 2006 Jul 1;177(1):501-10
pubmed: 16785547
Mech Ageing Dev. 2007 Jan;128(1):161-7
pubmed: 17126887
Clin Vaccine Immunol. 2010 Jun;17(6):919-29
pubmed: 20375242
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14823-8
pubmed: 26627237
Methods Mol Biol. 2012;799:1-20
pubmed: 21993636
Biochem J. 2016 Dec 15;473(24):4699-4713
pubmed: 27784765
Nat Commun. 2018 Feb 6;9(1):528
pubmed: 29410413
Clin Epidemiol. 2012;4:237-45
pubmed: 23071402
Infect Immun. 2015 Apr;83(4):1536-45
pubmed: 25644002
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17128-33
pubmed: 25404323
Sci Rep. 2016 Aug 17;6:31458
pubmed: 27530334
mBio. 2015 Jun 23;6(3):e00842
pubmed: 26106082
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 May 1;67(Pt 5):531-5
pubmed: 21543855
J Immunol. 1987 Jun 15;138(12):4402-7
pubmed: 3108388
Vaccine. 2011 Jun 24;29(29-30):4728-34
pubmed: 21571025
Sci Rep. 2012;2:341
pubmed: 22461972
Science. 2001 Aug 10;293(5532):1155-9
pubmed: 11498595
J Mol Biol. 2006 Apr 14;357(5):1566-74
pubmed: 16497332
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2714-9
pubmed: 26888286
Expert Rev Vaccines. 2011 Jan;10(1):21-33
pubmed: 21162617
Infect Immun. 2005 Feb;73(2):1151-60
pubmed: 15664958
J Biol Chem. 2009 Apr 3;284(14):9022-6
pubmed: 19196709
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Nature. 2009 Apr 16;458(7240):890-3
pubmed: 19225461
Expert Opin Pharmacother. 2004 Apr;5(4):855-63
pubmed: 15102568
Vaccine. 2013 Mar 15;31(12):1569-75
pubmed: 23352429
Mol Immunol. 2008 Jul;45(12):3477-89
pubmed: 18023478
Biochim Biophys Acta. 2010 Feb;1798(2):87-93
pubmed: 19835839
Infect Immun. 2008 Sep;76(9):4232-40
pubmed: 18591239
Trends Biochem Sci. 2010 Oct;35(10):539-46
pubmed: 20541943

Auteurs

Federica Bianchi (F)

GlaxoSmithKline, Siena, Italy.
University of Florence, Firenze, Italy.

Daniele Veggi (D)

GlaxoSmithKline, Siena, Italy.

Laura Santini (L)

GlaxoSmithKline, Siena, Italy.

Francesca Buricchi (F)

GlaxoSmithKline, Siena, Italy.

Erika Bartolini (E)

GlaxoSmithKline, Siena, Italy.

Paola Lo Surdo (P)

GlaxoSmithKline, Rockville, Maryland, USA.

Manuele Martinelli (M)

GlaxoSmithKline, Siena, Italy.

Oretta Finco (O)

GlaxoSmithKline, Siena, Italy.

Vega Masignani (V)

GlaxoSmithKline, Siena, Italy.

Matthew J Bottomley (MJ)

GlaxoSmithKline, Rockville, Maryland, USA.

Domenico Maione (D)

GlaxoSmithKline, Siena, Italy.

Roberta Cozzi (R)

GlaxoSmithKline, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH